
-
Replimune Group Inc NasdaqGS:REPL Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Location: 500 Unicorn Park Drive, Woburn, MA, 01801, United States | Website: https://www.replimune.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
314.7M
Cash
483.8M
Avg Qtr Burn
-48.06M
Short % of Float
17.39%
Insider Ownership
4.51%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RP1 +Opdivo (nivolumab) Details Cancer, Melanoma | PDUFA Approval decision | |
RP2 + Opdivo Details Cancer, Uveal melanoma | Phase 2/3 Data readout | |
RP1 + Opdivo Details Cancer, Non-melanoma skin cancer | Phase 2 Update | |
RP1 + Libtayo (cemiplimab) Details Cutaneous squamous cell carcinoma, Cancer | Phase 2 Update | |
RP2 in comb w/ atezolizumab and bevacizumab Details Cancer, Hepatocellular carcinoma | Phase 2 Initiation | |
RP1 Details Cancer, Cutaneous squamous cell carcinoma, Kidney transplantation, Liver transplant, Skin cancer | Phase 1/2 Data readout | |
RP2 +/- Opdivo Details Solid tumor/s, Cancer, Breast cancer, Head and neck cancer, Lung cancer, Hepatocellular carcinoma | Phase 1 Update | |
(RP3 & RP2) in comb w/atezolizumab and bevacizumab Details Cancer, Colorectal cancer , Hepatocellular carcinoma | Failed Discontinued | |
RP3 +/- Opdivo Details Solid tumor/s, Cancer, Lung cancer, Breast cancer, Head and neck cancer | Failed Discontinued | |
RP3 in comb w/std. of care Details Cancer, Head and neck squamous cell carcinoma | Failed Discontinued |